MedPath

Clinical Evaluation of Polycation-based New Dental Desensitizer on Dentin Hypersensitivity

Not Applicable
Active, not recruiting
Conditions
Dentin Sensitivity
Registration Number
NCT06378255
Lead Sponsor
Peking University Hospital of Stomatology
Brief Summary

Evaluate the safety and clinical efficacy of new dental desensitizers in the treatment of dentin sensitivity, including the relief of sensitivity symptoms and the duration of efficacy.

Detailed Description

This is a randomized, single-blind and controlled study to include 40 patients with dentin sensitivity. The study will be a randomized controlled trial with split mouth control, with two quadrants of the same patient as test and control groups, the test group being the group using the new desensitizer and the control group being the group with the clinically used desensitizer (Gruma desensitizer). Improvement in dentin sensitivity symptoms was the primary outcome indicator observed. Dentin sensitivity was assessed by evaluating the reduction in dentin sensitivity VAS scores at immediately, 1 month, 3 months, and 6 months points after the desensitization treatment, and by evaluating the subjects' self-reported relief of sensitivity. Safety was assessed by evaluating appliance defects and adverse events at the immediately,1-, 3-, and 6-months points after the desensitization treatment.

Recruitment & Eligibility

Status
ACTIVE_NOT_RECRUITING
Sex
All
Target Recruitment
40
Inclusion Criteria
  • Dentin Hypersensitivity, with Vas score≥4 points and the normal pulp viability
  • dentin-sensitive tooth in at least 2 different quadrants of the mouth (neck enamel dentin exposure or maxillofacial abrasion within the middle layer of dentin).
  • in good overall health
  • participants informed consent.
Exclusion Criteria
  • gastroesophageal reflux
  • Dental caries, wedge defects, crowns or large fillings.
  • Received dentin sensitivity desensitization treatment or used desensitization mouthwash within 1 month.
  • Received systematic periodontal therapy or periodontal surgery within 3 months, ongoing orthodontic treatment, and medical treatment, including long-term use of anti-inflammatory, analgesic, and psychotropic medications.
  • Pregnancy or breastfeeding.
  • Participated in other clinical trials in the past 3 months.

Study & Design

Study Type
INTERVENTIONAL
Study Design
PARALLEL
Primary Outcome Measures
NameTimeMethod
Improvement of dentin sensitivity induced by probe pressure stimulationAt Baseline and 10 minutes, 1 month, 3 months, 6 months after desensitization treatment

The severity of dentin sensitivity is assessed using visual analogue scale (VAS) with numbers 0-10 by participants after probe pressure stimulation. Beforehand, the participants were informed that the 10 cm VAS would be used to assess their pain sensitivity, with 0 indicating no pain and 10 indicating the worst pain. Lower scores on the VAS indicate lower sensitivity. Dentin sensitivity was considered to have improved if the visual pain scale (F-VAS) score decreased by 2 or more points from baseline.

Secondary Outcome Measures
NameTimeMethod
Improvement of dentin sensitivity induced by air temperature stimulationAt Baseline and 10 minutes, 1 month, 3 months, 6 months after desensitization treatment

The severity of dentin sensitivity is assessed using visual analogue scale (VAS) with numbers 0-10 by participants after cold air stimulation. Beforehand, the participants were informed that the 10 cm VAS would be used to assess their pain sensitivity, with 0 indicating no pain and 10 indicating the worst pain. Lower scores on the VAS indicate lower sensitivity. Dentin sensitivity was considered to have improved if the visual pain scale (F-VAS) score decreased by 2 or more points from baseline.

Trial Locations

Locations (1)

Peking University School and Hospital of Stomatology

🇨🇳

Beijing, Beijing, China

Peking University School and Hospital of Stomatology
🇨🇳Beijing, Beijing, China

MedPath

Empowering clinical research with data-driven insights and AI-powered tools.

© 2025 MedPath, Inc. All rights reserved.